MetLife Earnings: What To Look For From MET

MetLife (NYSE: MET) is set to report earnings Wednesday after market close. The prior quarter showed revenue of $19.68B, up 4.5% year over year, beating revenue estimates but missing book value per share. Analysts expect revenue growth of 8.8% year over year. MET’s average analyst price target is $97.75 versus $96.15.

Original reporting
Published Aug 4, 2026, 4:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 4:49 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MetLife Earnings: What To Look For From MET — source image
Decision brief

The 30-second read

$METNeutralMed
01

Why it matters

Traders can use the highlighted metrics (revenue growth and book value per share versus estimates) to frame positioning and options hedges into the after-hours print.

02

Market read

MET’s upcoming earnings are the central catalyst, with the article emphasizing prior estimate dynamics and what the market expects for revenue growth.

03

What to watch

The preview does not discuss guidance, capital position, or specific drivers of book value per share, which are often the real swing factors for life insurers’ post-earnings moves.

Relevance 4/10Novelty 4/10Timing: ahead of Wednesday after-hours earnings release

Background

The article is a pre-earnings checklist for MetLife, referencing last quarter’s results and current consensus expectations for revenue growth.

Company-level read

Ticker impact

$METNeutralMedium confidence
Context

MetLife (MET) is set to report earnings Wednesday after the close, with the article highlighting recent revenue and book value per share estimate misses.

Expected impact

Near-term volatility likely around the earnings release, with focus on whether revenue growth and book value per share align with expectations.

Evidence & confidence

This is a pre-earnings preview using previously reported results and consensus expectations, not a new disclosure; the most actionable element is the timing and what metrics the market will likely scrutinize.

Market effects

Could influence sentiment across life insurers by reinforcing what investors are rewarding (revenue/premiums) versus what they penalize (book value per share).

Primarily US-focused given the US-listed subject and peer references.

Limited, as the article does not introduce cross-border regulatory or macro shocks.

Counterpoint

If MET’s revenue growth and net premiums earned remain strong, the market may look through the prior book value per share miss and trade more on top-line momentum.

Key entities

  • MetLife

    US-listed life insurer scheduled to report earnings Wednesday after the close.

  • Jackson Financial

    Peer cited for Q2 revenue growth and a large miss versus expectations.

  • CNO Financial Group

    Peer cited for Q2 revenue topping estimates and a post-results stock move.

Related articles

$METMed

MetLife reports $1.6bn adjusted earnings in second quarter 2026

MetLife reported second-quarter 2026 adjusted earnings of $1.6bn. Net investment income rose 18% to $6.7bn. Book value per share increased 8% to $38.59 and adjusted book value per share rose 3% to $57.71. The company returned over $1.1bn to shareholders via buybacks and dividends, and reported segment adjusted earnings gains across Group Benefits, Retirement and Income Solutions, Asia, EMEA, and MetLife Investment Management.

$METMed

Financial results round-up: MetLife, Prudential, Corebridge, Palomar, Heritage, TWFG, Root and more

A financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.

$METMed

METLIFE INC (MET): Results of Operations and Financial Condition

METLIFE INC (MET) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 ex992qfs8kdoc.htm EX-99.2 Document Table of Contents Exhibit 99.2 Second Quarter Financial Supplement June 30, 2026 2 Table of Contents METLIFE TABLE OF CONTENTS GAAP CONSOLIDATED STATEMENTS OF OPERATIONS 2 CORPORATE OVERVIEW 3 KEY ADJUSTED EARNINGS STATEMENT LINE ITEMS

$METMedAI 8/10

MetLife profit rises on underwriting strength, volume growth

MetLife reported higher second-quarter adjusted profit, citing strong underwriting and broad volume growth. Premiums, fees and other revenue rose 7% to $13.7 billion. Group benefits adjusted profit increased 25% to $503 million, Asia earnings rose 21% and Latin America 15%. Net investment income climbed 18% to $6.7 billion, and adjusted EPS rose 20% to $2.43.

$DTMedAI 8/10

Dynatrace Springs on Q1 Figures

Dynatrace (NYSE: DT) reported Q1 FY2027 results for the quarter ended June 30, 2026. Total ARR was $2,136 million, up 17%. Total revenue rose to $555 million, up 16%. Subscription revenue was $530 million. GAAP operating income was $71 million and non-GAAP $162 million. CEO Rick McConnell cited 41% organic net new ARR growth and accelerating TTM growth.

$DBXMed

Dropbox Shares Decline Despite Earnings Beat as Revenue Growth Disappoints

Dropbox (DBX) shares fell about 5% premarket to around $32.80 after Q2 2026 results. The company reported adjusted EPS of $0.75 vs $0.74 expected and revenue of $631.5M vs about $627M, but revenue rose only 0.9% year over year. Non-GAAP operating margin improved to 39.7%. Paying users reached 18.19M. William Blair upgraded to Market Perform, while consensus remains Sell.